PYXS Pyxis Oncology, Inc. Stock Quote

PYXS [NASD]

Index	-	P/E	-	EPS (ttm)	-45.59	Insider Own	8.00%	Shs Outstand	32.32M	Perf Week	14.22%
Market Cap	78.73M	Forward P/E	-	EPS next Y	-3.74	Insider Trans	-40.69%	Shs Float	24.99M	Perf Month	-10.11%
Income	-	PEG	-	EPS next Q	-0.78	Inst Own	58.40%	Short Float	1.37%	Perf Quarter	-56.39%
Sales	-	P/S	-	EPS this Y	-501.70%	Inst Trans	3.42%	Short Ratio	1.97	Perf Half Y	-79.89%
Book/sh	7.23	P/B	0.34	EPS next Y	-4.70%	ROA	-	Target Price	18.00	Perf Year	-
Cash/sh	7.81	P/C	0.32	EPS next 5Y	-	ROE	-	52W Range	1.96 - 19.00	Perf YTD	-77.30%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-87.42%	Beta	-
Dividend %	-	Quick Ratio	13.10	Sales past 5Y	-	Gross Margin	-	52W Low	21.94%	ATR	0.28
Employees	64	Current Ratio	13.10	Sales Q/Q	-	Oper. Margin	-	RSI (14)	43.35	Volatility	10.93% 11.27%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	-594.20%	Profit Margin	-	Rel Volume	0.18	Prev Close	2.49
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	174.27K	Price	2.39
Recom	1.80	SMA20	2.62%	SMA50	-28.37%	SMA200	-69.39%	Volume	27,463	Change	-4.02%

Nov-02-21

Initiated

Jefferies

Buy

$25

Nov-02-21

Initiated

Credit Suisse

Outperform

$19

Nov-02-21

Initiated

BofA Securities

Neutral

$16

May-19-22 06:35AM	Pyxis Oncology Announces Presentations at Upcoming Investor Conferences GlobeNewswire
May-13-22 08:03AM	Pyxis Oncology Reports Financial Results for the Quarter Ended March 31, 2022 and Provides Business Update GlobeNewswire -9.01%
May-07-22 10:34AM	Will Pyxis Oncology (NASDAQ:PYXS) Spend Its Cash Wisely? Simply Wall St.
Apr-27-22 06:35AM	Pyxis Oncology to Participate in Fireside Chat at BofA Securities 2022 Healthcare Conference GlobeNewswire
Apr-13-22 06:35AM	Pyxis Oncology Announces Leadership Changes GlobeNewswire
Apr-08-22 01:05PM	Pyxis Oncology Announces Preclinical Data on Anti-Siglec-15 BSI-060T (PYX-106) Presented by Biosion, Inc. at the 2022 American Association for Cancer Research (AACR) Annual Meeting GlobeNewswire
Mar-29-22 11:00AM	Biosion licenses BSI-060T (anti-Siglec-15) to Pyxis Oncology PR Newswire
06:35AM	Pyxis Oncology Provides Corporate and Financial Update GlobeNewswire
Mar-22-22 06:35AM	Pyxis Oncology to Host Corporate Update Conference Call and Webcast on March 29, 2022 GlobeNewswire -8.04%
Jan-10-22 11:17AM	Quite a few insiders invested in Pyxis Oncology, Inc. (NASDAQ:PYXS) last year which is positive news for shareholders Simply Wall St.
Dec-15-21 08:00AM	Pyxis to be Added to Russell 2000® Index GlobeNewswire
Dec-09-21 08:30AM	Pyxis Oncology Appoints Martina Molsbergen as Interim Chief Business Officer GlobeNewswire
Nov-15-21 07:15AM	Pyxis Reports Financial Results for the Third Quarter of 2021 and Provides Business Update GlobeNewswire
Nov-10-21 08:00AM	Pyxis Oncology to Present at the Jefferies London Healthcare Conference GlobeNewswire
Oct-08-21 03:31PM	Pyxis Oncology well positioned to advance its work against cancer amid public debut: CEO Yahoo Finance Video
Oct-07-21 10:24PM	Pyxis Announces Pricing of Upsized Initial Public Offering GlobeNewswire

Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors. The company's antibody drug conjugate (ADC) product candidates comprise of PYX-201, an investigational novel ADC to treat NSCLC, breast cancer, and other solid tumors; PYX-202, an investigational novel ADC for treatment of SCLC, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational ADC for the treatment of acute myeloid leukemia and myeloid dysplastic syndrome. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Chin Mark	Former Director	Apr 21	Sale	3.05	1,745,761	5,324,571	0	Apr 25 12:12 PM
Cline Darren S	Director	Dec 08	Buy	9.39	10,000	93,885	10,000	Dec 09 04:18 PM
Civik Thomas	Director	Nov 18	Buy	12.74	15,700	200,018	15,700	Nov 19 01:21 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience